Darnytsia Pharmaceutical Company continues to expand its international presence. On December 22, 2025, an injectable medicinal product developed by Darnytsia was officially registered in Bosnia and Herzegovina. The product is used for the treatment and prevention of neuromuscular transmission disorders, including myasthenia gravis, stimulation of bowel and bladder function following surgical procedures, and the restoration of muscle activity after anesthesia.
The marketing authorization is valid for five years, granting patients in Bosnia and Herzegovina access to modern European pharmacotherapy that meets international standards of safety and efficacy.
The entry of Ukrainian medicines into international markets is further evidence of the high quality and global competitiveness of Darnytsia’s products.
“Each new market represents not only export growth, but also recognition of Ukrainian pharmaceuticals and improved access to modern treatment for patients in Europe. We achieved results where many said it was ‘impossible,’ thanks to teamwork and perseverance,” commented Hurhen Karapetian, Export & Hospital Sales Director at Darnytsia Pharmaceutical Company.
“Behind every international registration lies not only professionalism, but also a commitment to transforming the market and opening new opportunities for Ukrainian pharmaceuticals. Despite doubts and obstacles, we found a way forward and proved that a well-coordinated team is capable of achieving major results. This inspires us to continue exploring new horizons,” added Anna Pavliuk-Havrylova, Head of International Registration and New Market Entry at Darnytsia Pharmaceutical Company.
It should be noted that Darnytsia recently also registered a medicinal product from the systemic antimycotic group for the treatment and prevention of fungal infections in Bosnia and Herzegovina.
Darnytsia continues to systematically expand its international footprint, with the company’s products now represented in more than 20 countries worldwide.
